Article Sidebar
Published:
Jul 11, 2024DOI:
10.4314/ahs.v24i2.8Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccessTM study
Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) is a prevalent health burden, both in South Africa and globally. The treatment of MDR-TB is both complex and difficult as multiple drugs have to be used concurrently in order to achieve good treatment outcomes for patients. However, there is a lack in the evidence regarding the incidences of specific adverse effects of these drugs.
Objective: The main aim/objective of this study was to investigate and compare reported specific adverse drug reactions (ADRs) associated with kanamycin, capreomycin, amikacin and bedaquiline in MDR-TB patients.
Methods: Secondary data collected over a period of 12 months were sourced from a public access data base, VigiAccessTM, and analysed.
Results: There was a steep increase in adverse drug reactions reported for kanamycin with the main adverse reactions being hypoacusis, deafness and tinnitus cases, along with vomiting, nausea and diarrhoea. With capreomycin, there were increases in asthenia and hypoacusis although the latter showed a plateau after some point. Rash and pruritus increased along with cases of death with amikacin and there were reports of prolonged QT interval in the electrocardiogram of patients on bedaquiline in addition to nausea, vomiting and diarrhoea.
Conclusion: There are many specific adverse effects associated with kanamycin, capreomycin, amikacin and bedaquiline. The number of cases of the specific adverse effects also increased with time. Therefore, VigiAccessTM provides a good platform for reporting and awareness of specific adverse effects associated with MDR-TB therapy. This is a vital stepping stone for further research.
Keywords: Kanamycin; Amikacin; Capreomycin; Bedaquiline.
